Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
Kraynyak KA, Blackwood E, Agnes J, Tebas P, Giffear M, Amante D, Reuschel EL, Purwar M, Christensen-Quick A, Liu N, Andrade VM, Diehl MC, Wani S, Lupicka M, Sylvester A, Morrow MP, Pezzoli P, McMullan T, Kulkarni AJ, Zaidi FI, Frase D, Liaw K, Smith TRF, Ramos SJ, Ervin J, Adams M, Lee J, Dallas M, Shah Brown A, Shea JE, Kim JJ, Weiner DB, Broderick KE, Humeau LM, Boyer JD, Mammen MP. Kraynyak KA, et al. J Infect Dis. 2022 Jun 1;225(11):1923-1932. doi: 10.1093/infdis/jiac016. J Infect Dis. 2022. PMID: 35079784 Free PMC article. Clinical Trial.
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.
Tebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, Andrade VM, Morrow MP, Kraynyak K, Agnes J, Purwar M, Sylvester A, Pawlicki J, Gillespie E, Maricic I, Zaidi FI, Kim KY, Dia Y, Frase D, Pezzoli P, Schultheis K, Smith TRF, Ramos SJ, McMullan T, Buttigieg K, Carroll MW, Ervin J, Diehl MC, Blackwood E, Mammen MP, Lee J, Dallas MJ, Brown AS, Shea JE, Kim JJ, Weiner DB, Broderick KE, Humeau LM. Tebas P, et al. EClinicalMedicine. 2021 Jan;31:100689. doi: 10.1016/j.eclinm.2020.100689. Epub 2020 Dec 24. EClinicalMedicine. 2021. PMID: 33392485 Free PMC article.
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines.
Patel A, Reuschel EL, Kraynyak KA, Racine T, Park DH, Scott VL, Audet J, Amante D, Wise MC, Keaton AA, Wong G, Villarreal DO, Walters J, Muthumani K, Shedlock DJ, de La Vega MA, Plyler R, Boyer J, Broderick KE, Yan J, Khan AS, Jones S, Bello A, Soule G, Tran KN, He S, Tierney K, Qiu X, Kobinger GP, Sardesai NY, Weiner DB. Patel A, et al. Among authors: kraynyak ka. J Infect Dis. 2019 Jan 29;219(4):544-555. doi: 10.1093/infdis/jiy537. J Infect Dis. 2019. PMID: 30304515
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
Tebas P, Kraynyak KA, Patel A, Maslow JN, Morrow MP, Sylvester AJ, Knoblock D, Gillespie E, Amante D, Racine T, McMullan T, Jeong M, Roberts CC, Park YK, Boyer J, Broderick KE, Kobinger GP, Bagarazzi M, Weiner DB, Sardesai NY, White SM. Tebas P, et al. Among authors: kraynyak ka. J Infect Dis. 2019 Jul 2;220(3):400-410. doi: 10.1093/infdis/jiz132. J Infect Dis. 2019. PMID: 30891607
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML. Trimble CL, et al. Among authors: kraynyak ka. Lancet. 2015 Nov 21;386(10008):2078-2088. doi: 10.1016/S0140-6736(15)00239-1. Epub 2015 Sep 17. Lancet. 2015. PMID: 26386540 Free PMC article. Clinical Trial.
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100.
Morrow MP, Kraynyak KA, Sylvester AJ, Shen X, Amante D, Sakata L, Parker L, Yan J, Boyer J, Roh C, Humeau L, Khan AS, Broderick K, Marcozzi-Pierce K, Giffear M, Lee J, Trimble CL, Kim JJ, Sardesai NY, Weiner DB, Bagarazzi ML. Morrow MP, et al. Among authors: kraynyak ka. Mol Ther Oncolytics. 2016 Nov 30;3:16025. doi: 10.1038/mto.2016.25. eCollection 2016. Mol Ther Oncolytics. 2016. PMID: 28054033 Free PMC article.
Delineating the Cellular Mechanisms Associated with Skin Electroporation.
Schultheis K, Smith TRF, Kiosses WB, Kraynyak KA, Wong A, Oh J, Broderick KE. Schultheis K, et al. Among authors: kraynyak ka. Hum Gene Ther Methods. 2018 Aug;29(4):177-188. doi: 10.1089/hgtb.2017.105. Epub 2018 Aug 10. Hum Gene Ther Methods. 2018. PMID: 29953259 Free PMC article.
Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis.
Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Cheung J, Dickerson K, Schulten V, Knoblock D, Gillespie E, Bauml JM, Yan J, Diehl M, Boyer J, Dallas M, Kim JJ, Weiner DB, Skolnik JM. Aggarwal C, et al. Among authors: kraynyak ka. Vaccines (Basel). 2020 Jan 29;8(1):56. doi: 10.3390/vaccines8010056. Vaccines (Basel). 2020. PMID: 32013270 Free PMC article.
28 results